Vertellus shares insight on Hollow Fibre Membranes (HFM) in biopharmaceuticals and how it became a crucial part of the biotech industry’s value chain in recent years.
The Role of Hollow Fibre Membranes in the Biopharmaceutical Value-Chain
The use of hollow fibre membranes (HFM) in the continuous production of biologics has long been established. However, it was not until the pandemic afforded a rapid increase in investment and accelerated regulatory support that hollow fibre technology became a crucial part of the biotech industry’s value chain, particularly for vaccine and viral vector manufacturing. The fast-evolving bio-manufacturing landscape has created an opening for continuous bioprocessing, which is widely recognised as a technology for reducing manufacturing cost, while providing more flexibility and scalability with improved product quality.